poly(ADP-ribose) polymerase family member 11Genealiases: ARTD11 · C12orf6 · MIB006
Q-omics provides the consensus-scored PARP11 profile across patient tissues and cancer cell-line models. PARP11 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, PARP11 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, PARP11 RNA expression shows 20,953 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SKCM, HNSC, and UVM as cancer lineages where PARP11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PARP11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PARP11 survival associations across molecular data types. PARP11 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PARP11 RNA expression–survival associations across cancer types. High PARP11 expression shows unfavorable associations in HNSC and LGG, but favorable associations in SKCM, KIRC, LUAD and BRCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for PARP11 RNA expression.
This table summarizes PARP11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for PARP11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PARP11 shows lower tumor expression in THCA, UCEC, KICH and LUAD and higher tumor expression in HNSC and CHOL. The HNSC box plot shows higher PARP11 RNA expression in tumor versus normal tissue (log2 FC = +0.766, t-test p < 0.001).
This table shows molecular features associated with PARP11 in patient tissues and cancer cell lines. In patient samples, PARP11 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PARP11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
